Blood
Articles in this Issue
Mapping activated microglial density in individuals with sickle cell disease utilizing time-dependent diffusion-weighted MRI and correlation with cognitive performance
Abstract Introduction: Sickle cell disease (SCD) causes progressive cognitive deficits that begin in childhood. Other factors beyond neurova...
Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma
Abstract Background: Single-antigen CD19-targeting chimeric antigen receptor (CAR) T-cell therapies have become a standard of care for patie...
MRD-guided outcome analysis of ponatinib plus hyper-CVAD versus historical imatinib in ph-positive ALL: Impact of early response and dose-adjusted ponatinib
Abstract Background : The treatment strategies and outcomes of Philadelphia chromosome (Ph)-positive ALL have markedly improved with the deve...
Management of hemophilia and hemophilia carriers
Abstract Introduction: Historically, hemophilia has been viewed as primarily affecting individuals assigned male at birth (“males”) due to i...
Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031
Abstract Introduction Patients with acute myeloid leukemia (AML) with an internal tandem duplication mutation of FLT3 (FLT3/ITD) have a high...
Mecapegfilgrastim for prophylaxis of immunochemotherapy-induced neutropenia in patients with diffuse large B-cell lymphoma: A multicenter pilot trial
Abstract Introduction: R-CHOP is the current standard first-line treatment for diffuse large B-cell lymphoma (DLBCL). Chemotherapy-induced n...
Real-world outcomes, access, and role of autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma among AYAs and non-AYAs: A multicenter study from Peru
Abstract Introduction: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) continues to pose a significant clinical challenge,...
AP-3 targets the mrgbp/Tip60/MYC axis to exert potent anti T-ALL effects in a Notch1 independent manner
Abstract Background: T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive and lethal hematologic malignancy, accounting for 15%...
Abnormal metabolic activation of CD8+ t cells correlates with poor prognosis in acute myeloid leukemia
Abstract While conferring a superior graft-versus-leukemia (GVL) effect and achieving comparable outcomes to HLA-matched sibling donor trans...
Role of IL-10 in regulating macrophage pyroptosis in immune thrombocytopenia
Abstract Introduction Primary immune thrombocytopenia (ITP) is the most prevalent hemorrhagic disorder in clinical practice, with relapse an...
Control of gvhd by probiotics with a single strain of muribaculaceae bacterium through secretory proteins
Abstract Background Hematopoietic cell transplantation (HCT) is an effective approach to cure hematologic malignancies, but graft-versus-hos...
High vs. low intensity chemotherapy in AML: Survival and transplant outcomes in a brazilian experience
Abstract Although the treatment landscape for acute myeloid leukemia (AML) has evolved with the incorporation of targeted therapies—such as...
Quantifying treatment-associated monocytic differentiation in AML using a single-cell based myeloid differentiation index (MDX)
Abstract Background: Acute Myeloid Leukemia (AML) is a heterogeneous malignancy in which impaired myeloid differentiation, particularly towa...
Clinical outcomes in patients with accelerated or blast-Phase MPN treated with triplet regimen of hypomethylating agent, JAK inhibitor, and venetoclax (HMA/JAKi/Ven): A multicenter case series
Abstract Background: Myeloproliferative neoplasm in accelerated or blast phase (MPN-AP/BP) carries a dismal prognosis of 3-5 months with all...
Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study
Abstract Introduction: Epcoritamab (epco) and glofitamab (glofit) are bispecific antibodies (BsAbs) approved for the treatment of patients (...
Antibody- and equipment-free, ultralow-cost point-of-care sickle cell disease diagnostic: An equitably accessible powerful assay
Abstract Sickle cell disease (SCD) is the most prevalent inherited hematologic disorder worldwide. The global burden of SCD has markedly inc...
SKP2/CKS1B as a rational drug target in 1q21 amplified multiple myeloma.
Abstract Chromosome 1q21 amplification is closely associated with disease progression and adverse prognosis in multiple myeloma (MM), rising...
AML1/ETO upregulates fatty acid metabolism to induce venetoclax resistance in acute myeloid leukemia via activation of c-myc/SCD1 pathway
Abstract Several studies including ours demonstrate that AML1/ETO-positive acute myeloid leukemia (AML) has poor response to venetoclax (Ven...
Cly-124, a first-in-class DCN1 inhibitor partially suppresses CUL3 neddylation and induces fetal hemoglobin is a new potential treatment for sickle cell disease
Abstract Sickle cell disease (SCD) is an inherited blood disorder caused by a mutation in the beta-globin gene resulting in hemoglobin polym...
Inflammation-triggered thrombotic thrombocytopenic purpura: A case series highlighting diagnostic pitfalls and atypical presentations
Abstract Background Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy marked by thrombocyto...
Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101
Abstract Introduction: Combination therapy with zanubrutinib, obinutuzumab, and venetoclax has demonstrated efficacy in patients with TN CLL/...
CD19/22 CAR T-cells in children and young adults with B-ALL: Final Phase 1 trial results
Abstract Introduction: Initial experience from the dose-escalation portion of our phase 1 bivalent CD19.22.BBζ in children and young adults...
Artificial intelligence -driven GVHD scoring and response tracking: Advancing FACT compliance, clinical trial readiness, and evidence-based therapy in a transplant program
Abstract Introduction : Graft-versus-host disease (GvHD) remains a major challenge in allogeneic transplantation. Despite standardized gradi...
Real-world validation of the molecular prognostic risk signature in acute myeloid leukemia treated with hypomethylating agents plus BCL-2 inhibitor.
Abstract Introduction: Response to hypomethylating agents (HMA) plus BCL-2 inhibitor is a key determinant of clinical outcomes in elderly Ac...
Concurrent TP53 loss-of-function and epigenetic modifier mutations as a potential predictor of chemoimmunotherapy failure in DLBCL & hgbl
Abstract Background: Despite the efficacy of modern chemoimmunotherapy, a significant subset of patients with diffuse la...